19 studies found for:    "Diffuse systemic sclerosis"
Show Display Options
Rank Status Study
1 Recruiting IL1-TRAP, Rilonacept, in Systemic Sclerosis
Conditions: Scleroderma;   Systemic Sclerosis;   Diffuse Scleroderma;   Diffuse Systemic Sclerosis
Interventions: Drug: Rilonacept;   Drug: Placebo
2 Unknown  Serial Night Time Position Splint on Systemic Sclerosis
Condition: Diffuse Systemic Sclerosis
Interventions: Device: Serial night time position splint;   Drug: Drug treatment
3 Completed Fresolimumab In Systemic Sclerosis
Condition: Diffuse Systemic Sclerosis
Intervention: Drug: Fresolimumab
4 Completed A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma
Conditions: Limited Scleroderma;   Diffuse Scleroderma
Intervention:
5 Recruiting IVIG Treatment in Systemic Sclerosis
Conditions: Systemic Sclerosis;   Diffuse Scleroderma
Intervention: Biological: Privigen
6 Unknown  Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Ambrisentan with an anti-fibrotic agent to assess benefit on skin.
7 Recruiting Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention: Drug: Belimumab
8 Unknown  High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis
Condition: Scleroderma, Diffuse
Intervention: Drug: N-acetylcysteine (NAC)
9 Completed Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody
10 Unknown  AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis
Condition: Systemic Sclerosis
Interventions: Drug: Hyperimmune caprine serum;   Drug: Albumin
11 Completed Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma
Condition: Systemic Sclerosis
Intervention: Drug: Relaxin
12 Completed Mycophenolate Mofetil in Systemic Sclerosis
Condition: Diffuse Cutaneous Systemic Sclerosis
Intervention: Drug: Mycophenolate Mofetil
13 Terminated Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma
Condition: Scleroderma
Interventions: Drug: Imatinib mesylate;   Other: Placebo
14 Recruiting Highdose Chemotherapy and Transplantation of 34+ Selected Stem Cell for Progressive Systemic Sclerosis - Modification According to Manifestation
Conditions: Scleroderma;   Cardiac Involvement;   Autologous Stem Cell Transplantation
Intervention: Drug: Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells
15 Terminated Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis
Condition: Scleroderma, Systemic
Interventions: Drug: Thalidomide;   Drug: Placebo thalidomide
16 Completed Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis
Condition: Systemic Sclerosis
Interventions: Drug: anti-thymocyte globulin;   Drug: cyclophosphamide
17 Completed A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)
Conditions: Scleroderma, Diffuse;   Scleroderma, Systemic
Intervention: Drug: Abatacept
18 Completed Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention: Drug: relaxin
19 Active, not recruiting Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Condition: Systemic Sclerosis
Interventions: Drug: SAR100842;   Drug: Placebo

Indicates status has not been verified in more than two years